Oncogene Cancer Research — shared on X:
“How do we create better surgical outcomes for early stage EGFR lung cancer as neoadjuvant immuno is not indicated?
MSK Cancer Center shared pre‑surgery osimertinib (w or w/o chemo) led to major tumour shrinkage in EGFR lung cancer at ASCO.”
Oncogene Cancer Research referenced new findings from Memorial Sloan Kettering Cancer Center presented at ASCO, showing that pre-surgery osimertinib—with or without chemotherapy—led to significant tumor shrinkage in early-stage EGFR lung cancer where neoadjuvant immunotherapy is not indicated.
Find More Posts Featuring EGFR lung cancer on OncoDaily